Mazdutide is a once-weekly injectable that activates both GLP-1 and glucagon receptors. It's approved in China but not FDA-approved in the US. Here's what the research shows, and how TelosRX handles approved GLP-1 options instead.
Mazdutide went from obscure trial code to trending search in a few months. People keep asking where it fits next to tirzepatide and retatrutide. Short version: it's a real drug with real phase 3 data, but you can't get it legally in the US yet.
Below are seven things worth knowing, in plain English. Every number links back to a published study.
1. Mazdutide Is a Dual GLP-1 and Glucagon Agonist
Mazdutide targets two hormone receptors at once: GLP-1 and glucagon. Scientists built it as an analog of oxyntomodulin, a gut hormone that naturally hits both receptors.
The GLP-1 side works like semaglutide. It slows stomach emptying and turns down appetite signals. If you want the backstory, our guide to the incretin effect covers how this hormone family works.
The glucagon side is the twist. Glucagon is studied for raising energy use and pulling fat out of the liver. The bet is that pairing both signals adds up to more than either alone.
- Drug class: GLP-1/glucagon dual receptor agonist
- Other names: IBI362, LY3305677
- Dosing schedule in trials: once-weekly injection under the skin
- Developers: Innovent in China; Eli Lilly outside China
2. It's Approved in China, Not in the US
China's drug regulator approved mazdutide for chronic weight management in June 2025. That made it the first GLP-1/glucagon dual agonist approved anywhere.
In the US, mazdutide is still investigational. It is not FDA-approved for any use. Eli Lilly is running its own trials under the code LY3305677, including studies in adults with obesity or overweight.
So any US website "selling mazdutide" is selling an unapproved research chemical. Purity, dose, and sterility are anyone's guess. That's a hard pass.
3. The Phase 3 Weight Data Is Strong
Two large Chinese trials anchor the evidence. Both ran close to a year or longer, with diet and activity advice in every group.
The GLORY-1 trial in the New England Journal of Medicine enrolled 610 adults. They received 4 mg, 6 mg, or placebo for 48 weeks. Both doses produced clinically meaningful weight reduction versus placebo, with the 6 mg arm averaging a mid-teens percentage drop.
The higher-dose follow-up, GLORY-2 in JAMA, tested 9 mg over 60 weeks. The study reported an average body-weight change of about −16.7% with mazdutide versus −1.5% with placebo.
| Trial | Dose | Length | Reported result vs placebo |
|---|---|---|---|
| GLORY-1 (NEJM, 2025) | 4 mg and 6 mg weekly | 48 weeks | Clinically meaningful reduction at both doses; larger at 6 mg |
| GLORY-2 (JAMA, 2026) | 9 mg weekly | 60 weeks | About −16.7% vs −1.5% average body-weight change |
One caveat matters. Both trials enrolled Chinese adults only. Results in other populations may differ, which is why Lilly's global trials matter.
4. Waist, Blood Pressure, and Lipids Moved Too
Weight wasn't the only thing that shifted. GLORY-2 also reported smaller waists, lower systolic blood pressure, and lower triglycerides in the mazdutide group.
GLORY-1 reported a notable drop in liver fat among people who started with a fatty liver. That fits the glucagon theory. Still, liver-specific trials are needed before anyone draws firm conclusions.
- Waist circumference: larger reduction than placebo in GLORY-2
- Systolic blood pressure: lower with mazdutide in GLORY-2
- Triglycerides and non-HDL cholesterol: improved in GLORY-2
- Liver fat: reduced in GLORY-1 participants with higher baseline liver fat
5. Side Effects Look Familiar, and Frequent
Mazdutide's side effects mirror other GLP-1 drugs. Stomach issues lead the list, mostly during dose increases.
In GLORY-2, vomiting, nausea, and diarrhea were each reported by a large share of people on 9 mg. Most cases were mild to moderate. Only about 3% stopped the drug because of side effects.
The trials also noted a transient rise in heart rate. A few cases of gallbladder problems appeared in the mazdutide group as well. Long-term safety data beyond about a year and a half is still thin.
Want a GLP-1 option you can actually access? Compare the GLP-1 options at TelosRX. Every prescription is subject to medical approval by a licensed provider, and compounded versions are not FDA-approved.
6. Mazdutide vs Retatrutide vs Tirzepatide
"Mazdutide vs retatrutide" is one of the fastest-rising searches around this drug. The core difference is how many receptors each one hits.
| Feature | Mazdutide | Retatrutide | Tirzepatide |
|---|---|---|---|
| Receptors | GLP-1 + glucagon | GIP + GLP-1 + glucagon | GIP + GLP-1 |
| Agonist type | Dual | Triple | Dual |
| Dosing | Once weekly | Once weekly (in trials) | Once weekly |
| US FDA status | Not approved | Not approved | Approved as Mounjaro and Zepbound |
| Approved anywhere? | China (2025) | No | Yes, US and other markets |
Retatrutide adds a third receptor, GIP. Its phase 2 trial in the New England Journal of Medicine reported average weight reduction of up to 24.2%. That was at 48 weeks on the top dose. We break that drug down further in retatrutide vs tirzepatide.
Cross-trial comparisons are shaky. Different populations, doses, and trial lengths make head-to-head conclusions unreliable. Only tirzepatide, among these three, has FDA approval in the US today.
7. It's Part of a Bigger Wave of Next-Gen GLP-1 Drugs
Mazdutide isn't alone. Several companies are testing multi-receptor drugs that go beyond GLP-1 alone.
- Survodutide: another GLP-1/glucagon dual agonist in late-stage trials
- Retatrutide: the GIP/GLP-1/glucagon triple agonist
- CagriSema: semaglutide paired with the amylin analog cagrilintide (see our CagriSema Q&A)
- Eloralintide: an amylin-based drug in clinical testing
None of these are FDA-approved yet. Expect a few to reach US pharmacies over the next several years, assuming trials hold up.
What This Means for You Right Now
If mazdutide caught your eye, the underlying goal is usually the same: a weekly medication that helps with appetite and weight. FDA-approved options for that already exist.
Tirzepatide is the closest relative available today. Learn how the TelosRX tirzepatide program works. The process is asynchronous: you complete an online intake, and a licensed provider reviews it on their own schedule. Any prescription is subject to medical approval by a licensed provider.
Skip "research use only" vials of mazdutide. Without approval and pharmacy oversight, you can't verify what's inside.
Frequently Asked Questions
Is mazdutide FDA-approved?
No. Mazdutide is not FDA-approved for any use in the United States. China approved it for chronic weight management in June 2025. Eli Lilly is running trials outside China under the code LY3305677. Until the FDA reviews and approves it, US patients can only access it through enrolled clinical trials.
What is the difference between mazdutide and retatrutide?
Mazdutide is a dual agonist that activates GLP-1 and glucagon receptors. Retatrutide is a triple agonist that adds the GIP receptor on top of those two. Both are weekly injections studied for weight management. Neither is FDA-approved, and no completed trial has compared them head to head, so claims that one is better are speculation.
Is mazdutide better than tirzepatide?
There's no head-to-head trial to answer that. Tirzepatide hits GIP and GLP-1 receptors, while mazdutide hits GLP-1 and glucagon. Tirzepatide is FDA-approved and has large international trial data. Mazdutide's phase 3 data so far comes from Chinese adults. A licensed provider can review which approved option fits your health history.
What are the side effects of mazdutide?
Trials report mostly gastrointestinal side effects, including nausea, vomiting, and diarrhea, especially during dose increases. Most were mild to moderate. Researchers also noted a temporary rise in heart rate and a few gallbladder events. Long-term safety data is still limited, which is one reason regulators outside China haven't approved it yet.
Is mazdutide a peptide?
Yes. Mazdutide is a synthetic peptide modeled on oxyntomodulin, a natural gut hormone. It's modified to last long enough for once-weekly dosing. Being a peptide doesn't make it a "research peptide" you can buy safely online. In the US it remains an investigational drug, and unapproved vials carry purity and dosing risks.
Can I get mazdutide in the US?
Not legally outside a clinical trial. You can search ClinicalTrials.gov for enrolling mazdutide or LY3305677 studies. Products sold online as mazdutide are unapproved and unverified. If you want a weekly GLP-1 medication now, FDA-approved options such as tirzepatide and semaglutide exist, subject to medical approval by a licensed provider.
How much weight did people lose on mazdutide in trials?
In the GLORY-2 trial in JAMA, adults on 9 mg averaged about −16.7% body-weight change at 60 weeks. Placebo averaged −1.5%. GLORY-1 reported meaningful reductions at 4 mg and 6 mg over 48 weeks. Individual results vary, and these trials enrolled Chinese adults only.
TelosRX is LegitScript-certified. Compounded medications are not FDA-approved and are prepared under federal compounding regulations. Approval is subject to evaluation by a licensed provider; approval is not guaranteed. Individual results vary. TelosRX operates as an online-first, asynchronous telehealth service.
Start your private evaluation at TelosRX.